Sun Pharmaceutical Industries continues to prioritise organic growth, disciplined capital allocation and innovation-led expansion, even as it selectively evaluates acquisition opportunities to strengthen its long-term strategic capabilities, Chairman Dilip Shanghvi said during the company’s latest earnings call. The US remains a core market for Sun Pharma, particularly for its innovative medicines portfolio, while the company […]